RT Journal Article
SR Electronic
T1 Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.27.23289228
DO 10.1101/2023.04.27.23289228
A1 Gross, Rachel
A1 Thaweethai, Tanayott
A1 Rosenzweig, Erika B.
A1 Chan, James
A1 Chibnik, Lori B.
A1 Cicek, Mine S.
A1 Elliott, Amy J.
A1 Flaherman, Valerie J.
A1 Foulkes, Andrea S.
A1 Witvliet, Margot Gage
A1 Gallagher, Richard
A1 Gennaro, Maria Laura
A1 Jernigan, Terry L.
A1 Karlson, Elizabeth W.
A1 Katz, Stuart D.
A1 Kinser, Patricia A.
A1 Kleinman, Lawrence C.
A1 Lamendola-Essel, Michelle F.
A1 Milner, Joshua D.
A1 Mohandas, Sindhu
A1 Mudumbi, Praveen C.
A1 Newburger, Jane W.
A1 Rhee, Kyung E.
A1 Salisbury, Amy L.
A1 Snowden, Jessica N.
A1 Stein, Cheryl R.
A1 Stockwell, Melissa S.
A1 Tantisira, Kelan G.
A1 Thomason, Moriah E.
A1 Truong, Dongngan T.
A1 Warburton, David
A1 Wood, John C.
A1 Ahmed, Shifa
A1 Akerlundh, Almary
A1 Alshawabkeh, Akram N.
A1 Anderson, Brett R.
A1 Aschner, Judy L.
A1 Atz, Andrew M.
A1 Aupperle, Robin L.
A1 Baker, Fiona C.
A1 Balaraman, Venkataraman
A1 Banerjee, Dithi
A1 Barch, Deanna M.
A1 Baskin-Sommers, Arielle
A1 Bhuiyan, Sultana
A1 Bind, Marie-Abele C.
A1 Bogie, Amanda L.
A1 Buchbinder, Natalie C.
A1 Bueler, Elliott
A1 Bükülmez, Hülya
A1 Casey, B.J.
A1 Chang, Linda
A1 Clark, Duncan B.
A1 Clifton, Rebecca G.
A1 Clouser, Katharine N.
A1 Cottrell, Lesley
A1 Cowan, Kelly
A1 D’Sa, Viren
A1 Dapretto, Mirella
A1 Dasgupta, Soham
A1 Dehority, Walter
A1 Dummer, Kirsten B.
A1 Elias, Matthew D.
A1 Esquenazi-Karonika, Shari
A1 Evans, Danielle N.
A1 Faustino, E. Vincent S.
A1 Fiks, Alexander G.
A1 Forsha, Daniel
A1 Foxe, John J.
A1 Friedman, Naomi P.
A1 Fry, Greta
A1 Gaur, Sunanda
A1 Gee, Dylan G.
A1 Gray, Kevin M.
A1 Harahsheh, Ashraf S.
A1 Heath, Andrew C.
A1 Heitzeg, Mary M.
A1 Hester, Christina M.
A1 Hill, Sophia
A1 Hobart-Porter, Laura
A1 Hong, Travis K.F.
A1 Horowitz, Carol R.
A1 Hsia, Daniel S.
A1 Huentelman, Matthew
A1 Hummel, Kathy D.
A1 Iacono, William G.
A1 Irby, Katherine
A1 Jacobus, Joanna
A1 Jacoby, Vanessa L.
A1 Jone, Pei-Ni
A1 Kaelber, David C.
A1 Kasmarcak, Tyler J.
A1 Kluko, Matthew J.
A1 Kosut, Jessica S.
A1 Laird, Angela R.
A1 Landeo-Gutierrez, Jeremy
A1 Lang, Sean M.
A1 Larson, Christine L.
A1 Lim, Peter Paul C.
A1 Lisdahl, Krista M.
A1 McCrindle, Brian W.
A1 McCulloh, Russell J.
A1 Mendelsohn, Alan L.
A1 Metz, Torri D.
A1 Morgan, Lerraughn M.
A1 Müller-Oehring, Eva M.
A1 Nahin, Erica R.
A1 Neale, Michael C.
A1 Ness-Cochinwala, Manette
A1 Nolan, Sheila M.
A1 Oliveira, Carlos R.
A1 Oster, Matthew E.
A1 Payne, R. Mark
A1 Raissy, Hengameh
A1 Randall, Isabelle G.
A1 Rao, Suchitra
A1 Reeder, Harrison T.
A1 Rosas, Johana M.
A1 Russell, Mark W.
A1 Sabati, Arash A.
A1 Sanil, Yamuna
A1 Sato, Alice I.
A1 Schechter, Michael S.
A1 Selvarangan, Rangaraj
A1 Shakti, Divya
A1 Sharma, Kavita
A1 Squeglia, Lindsay M.
A1 Stevenson, Michelle D.
A1 Szmuszkovicz, Jacqueline
A1 Talavera-Barber, Maria M.
A1 Teufel, Ronald J.
A1 Thacker, Deepika
A1 Udosen, Mmekom M.
A1 Warner, Megan R.
A1 Watson, Sara E.
A1 Werzberger, Alan
A1 Weyer, Jordan C.
A1 Wood, Marion J.
A1 Yin, H. Shonna
A1 Zempsky, William T.
A1 Zimmerman, Emily
A1 Dreyer, Benard P.
A1 the RECOVER Initiative
YR 2023
UL http://medrxiv.org/content/early/2023/05/01/2023.04.27.23289228.abstract
AB Importance The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or “Long COVID”) in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults.Observations We describe the protocol for the Pediatric Observational Cohort Study of the NIH’s REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of five cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n=10,000). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science.Conclusions and Relevance RECOVER-Pediatrics seeks to characterize the clinical course, underlying mechanisms, and long-term effects of PASC from birth through 25 years old. RECOVER-Pediatrics is designed to elucidate the epidemiology, four-year clinical course, and sociodemographic correlates of pediatric PASC. The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions.Clinical Trials.gov Identifier Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT05172011Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: Brett Anderson reported receiving direct support for work not related to RECOVER work/publications from Genentech and the National Institute of Allergy and Immunology. Walter Dehority reported receiving grant support from Merck and participating in research for the Moderna COVID-19 pediatric vaccine trial and the Pfizer Paxlovid trial. Alex Fiks reported receiving support from NJM insurance and personal consulting fees not related to this paper from Rutgers University and the American Academy of Pediatrics. Ashraf Harahsheh reported serving as a scientific advisory board member unrelated to this paper for OP2 DRUGS. Lawrence Kleinman reported serving as an unpaid member of the Board of Directors for the DARTNet Institute, as a principle investigator at Quality Matters, Inc., and as the Vice Chair for the Borough of Metuchen Board of Health. Dr. Kleinman also reported grant support for work not related to RECOVER work/publications from NIH, HRSA, and the Robert Wood Johnson Foundation. Dr. Kleinman also reported minority individual stock ownership in Apple Computer, Sanofi SA, Experion, GlaxoSmithKline, Magyar Bank, Regeneron Pharmaceuticals, JP Morgan Chase, and Amgen Inc. Torri Metz reported participating as a Principle Investigator in the medical advisory board for the planning of a Pfizer clinical trial of SARS-CoV-2 vaccination in pregnancy. She is also a principle investigator for a Pfizer study evaluating the pharmacokinetics of Paxlovid in pregnant people with COVID-19. Joshua Milner reported serving as a member of the Scientific Advisory Board for Blueprint Medicines, in a capacity unrelated to RECOVER work/publications.Clinical Protocols https://recovercovid.org/sites/default/files/docs/PediatricProtocol.v2.3.pdf Funding StatementNational Institutes of Health (NIH) Agreement OTA OT2HL161847 (SDK, RG), OT2HL161841 (ASF). https://www.nih.gov/ The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For NIH grant funded research approved before the revised Common Rule: the IRB has found the IRB approved protocol referenced above to be consistent with the NIH grant application. This approval letter serves as the approval for the abovementioned location(s) only. If your study is a multi-site study using NYU SoM IRB as the Single IRB, this approval letter does not serve as approval for participating sites. If your study is a multi-site study not requiring the use of a Single IRB, this approval does not serve as approval for any of the other sites. Each site will need to obtain IRB approval before human subjects research may commence at the site. NYU Grossman School of Medicine Federal wide Assurance: FWA00004952 NYU Winthrop/Long Island School of Medicine Federal wide Assurance: FWA00000726 NYU Langone Health operates in accordance with Good Clinical Practices (GCP) and applicable laws and regulations. Federal rules allow IRB to document their determination/authorization process in their policy manual. Determination letters generated by NYU Langone Health IRB administration system are not physically signed as per policy. All approved study materials are clearly identified and locked in each study submission record within the IRB’s administration system.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.